

**Client:** Akers Bioscience  
**Source:** Health Investor (Main)  
**Date:** 01 October 2008  
**Page:** 51  
**Circulation:** 4350  
**Size:** 111cm2  
**AVE:** 1110

---

M:

# company results

## AKERS BIOSCIENCES

Aim-listed Akers Biosciences (ABI), which makes diagnostic tests, recorded its first pre-tax profit and announced two new products. In the six months to 30 June 2008, the company made a profit of US\$251,000 (£141,000) on revenues of \$3.43 million, compared to a \$807,000 loss on \$2.13 million revenues in the same period last year.

Akers is developing a test to detect the presence of ketones in the breath of people with diabetes. High ketone levels are an indicator of the potentially life-threatening condition diabetic ketoacidosis. It is also planning to market a breath test which detects early chemical markers for lung cancer.

Chief executive Thomas Nicolette said: "The business is profitable from operations and generating positive cash flow. Our products have high volume potential in established markets and the company has a rich development pipeline of diagnostic tests with blockbuster potential."